Posted in M&A / Deals Lilly boosts ADC portfolio with CrossBridge Bio deal April 14, 2026 BioPharma Dive Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies. M&A / DealsOncologyRead full story